Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 14Metastatic Castration-resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 2Urologic Neoplasms 1Urologic Diseases 1Neoplasms 1Hypogonadism 1Fatigue 1Eunuchism 1Castration-Resistant Prostate Carcinoma 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × testosterone 17 beta-cypionate × Clear all
NCT00965341 2016-09-13

Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

M.D. Anderson Cancer Center

Phase 3 Completed
53 enrolled 8 charts

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡